Listed below are resources in Word and GIF format from Managing Anticoagulation Patients in the Hospital by Michael Gulseth. The documents followed by a are available to purchasers of the book and are password protected. If you have not received your password, please contact Jack Bruggeman at jbruggeman@ashp.org.

Quick Reference

• Pocket Reference for OralAnticoagulation [DOC]
• Heparin, LMWH, Fondaparinux Quick Reference Guide [DOC]
• Pocket Reference for DTI Therapy [DOC]

Business Plan

• St. Joseph Business Plan [DOC]

Figures

• Figure 4-6: ARMC Pharmacy Anticoagulation Service Flow Sheet [GIF]
• Figure 5-1: Recombinant Factor VIIa Orders [DOC]
• Figure 5-2: Anticoagulation Bridging Guidelines [DOC]
• Figure 5-3: Pharmacy Policy and Procedure Example for Pharmacist-Managed Warfarin Dosing [DOC]
• Figure 5-4: Conservative Warfarin Initiation Algorithm [GIF]
• Figure 5-5: Aggressive Warfarin Dose Initiation Nomogram [GIF]
• Figure 5-6: Anticoagulation Discharge Follow-up Orders [DOC]
• Figure 5-7: Warfarin Discharge Work Checklist [DOC]
• Figure 5-8: Daily INR Policy [DOC]
• Figure 5-9: Vitamin K Use Policy [DOC]
• Figure 5-10: Warfarin Anticoagulation Reversal Guidelines [DOC]
• Figure 5-11: Direct Thrombin Inhibitor Orders [DOC]
• Figure 5-12: Policy and Procedure for Pharmacy to Dose Direct Thrombin Inhibitors [DOC]
• Figure 5-13: Dosing Guidelines and Monitoring Form for Argatroban Anticoagulation that Can Be Modified to Other Direct Thrombin Inhibitors [DOC]
• Figure 6-1 [GIF]
• Figure 6-2 [GIF]
• Figure 7-3: Objective Criteria to Assure an Inpatient Anticoagulation Pharmacist is Competent in Practice [DOC]
• Figure 9-1: Percentage of INRs greater than 3.5 [GIF]
• Figure 9-2: Percentage of INRs greater than 6 [GIF]
• Figure 10-1: Vitamin K Cycle [GIF]
• Figure 10-2: Coagulation Cascade and Vitamin K-dependent Clotting Factor Half-lives [GIF]
• Figure 11-1: Mechanism of Action of UFH, LMWH, and Fondaparinux [GIF]

Tables

• Table 2-1a: Selected References Supporting Pharmacist Management of Heparin and Warfarin in the Inpatient Setting - Part 1 [GIF]
• Table 2-1b: Selected References Supporting Pharmacist Management of Heparin and Warfarin in the Inpatient Setting - Part 2 [GIF]
• Table 9-1: Process Measure Data Collection Form [GIF]
• Table 10-1: Clinically Significant Interactions with Warfarin by level of Causation and Drug Group [GIF]
• Table 10-2: Clinically Significant Interactions with Warfarin by Level of Causation and Drug Group (continued) [GIF]
• Table 11-1: Pharmacologic and Clinical Properties of UFH, LMWH, and Fondaparinux [GIF]
• Table 11-2: Sample Dosing and Monitoring Nomogram for Adjusted-dose Subcutaneous UFH [GIF]
• Table 11-3: Practical Considerations for Transitioning between Various Anticoagulate Agents [GIF]
• Table 11-4: Sample Weight-based Dosing Nomogram for IV UFH in Acute Thrombosis [GIF]
• Table 11-5: Sample Monitoring Nonogram for IV UFH [GIF]
• Table 11-6: Indications and Recommended Doses for LMWHs and Fondaparinux [GIF]
• Table 11-7: Sample LMWH Dosing Nomogram for Pediatric Patients [GIF]
• Table 11-8: Recommendations for Timing for Anticoagulate Agents in Patients Undergoing Neuraxial Procedures [GIF]
• Table 11-9: Dosing and Monitoring Considerations for LMWH and Fondaparinux in Patients with Renal Impairment [GIF]
• Table 12-1: Pharmacokinetics of Available Antithrombin Agents [GIF]
• Table 12-2: Steps in the Initiation, Monitoring, and Transition Off DTI Therapy [GIF]
• Table 12-3: Transitioning from a DTI to Warfarin [GIF]
• Table 13-1a: Anticoagulants in the Pipeline - Part 1 [GIF]
• Table 13-1b: Anticoagulants in the Pipeline - Part 2 [GIF]

Appendices

• Appendix 8-1: Patient Education Materials: Warfarin [DOC]
• Appendix 8-2: Patient Education Materials: Injectable Anticoagulants such as Enoxaparin and Dalteparin [DOC]

Password protected

• Print This Page
• Close Window